Phase 1 Trial of INCA33890 Alone or With Other Drugs for Advanced or Metastatic Solid Tumors

What this Trial Is About

Researchers are evaluating the safety, tolerability, dose limiting toxicities DLTs, and appropriate dosing levels of INCA33890 in adults with certain advanced or metastatic solid tumors. This Phase 1 open-label study focuses on participants who have experienced disease progression or are ineligible for existing therapies. The goal is to determine the maximum tolerated dose and recommended doses of INCA33890 alone or in combination with other cancer treatments. Participants receive INCA33890 either alone or combined with other drugs such as bevacizumab, FOLFIRI, FOLFOX, cetuximab, or ADG126 depending on their assigned study group. The administration follows protocol-defined dosing schedules based on cohort assignment, with treatment cycles lasting 28 days. The study includes dose escalation and expansion phases to evaluate monotherapy and multiple combination therapies. Throughout the study, participants undergo tumor biopsies, imaging to measure disease progression, and laboratory tests to monitor drug levels and side effects. Researchers track adverse events, dose modifications, and tumor response over up to two years. Pharmacokinetic parameters of INCA33890 are also measured during treatment cycles. Safety and treatment effects are closely monitored until the end of the study period, which may last several years.

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors